What Microbot Medical does

Microbot Medical, Inc. (NASDAQ: MBOT) is a medical device company developing and commercializing the LIBERTY® Endovascular Robotic System, the first FDA-cleared single-use, remotely operated robotic platform for peripheral endovascular procedures. Founded in 2012 and headquartered in Hingham, Massachusetts with manufacturing operations in Israel, the company has received FDA 510(k) clearance (September 2025), Israeli AMAR approval (May 2026), and has CE Mark application in progress. The LIBERTY system features a miniaturized, fully disposable form factor that can be set up in under five minutes, proprietary AccuGrip™ technology for secure guidewire and catheter manipulation, and remote operation capability that allows physicians to perform procedures from a seated position away from the radiation source — with clinical trials demonstrating a 92% relative reduction in physician radiation exposure and 100% procedural success with zero device-related adverse events.

The company's revenue model is a recurring per-procedure hardware sale of single-use LIBERTY units to hospitals, supplemented by non-dilutive grants from the Israel Innovation Authority tied to future sales royalties. Pricing is quote-based and not publicly disclosed; the company offers a "LIBERTY Starter Kit" to lower barriers to adoption by bundling clinical training and support. Microbot commercialized through a Limited Market Release beginning November 2025, followed by Full Market Release at the SIR Annual Scientific Meeting in April 2026, scaling direct U.S. enterprise field sales from 4 to 8 territories with a stated plan to reach 12 by year-end 2026. Distribution is augmented by a channel partnership with Lovell Government Services to reach 2,000+ federal healthcare facilities (VA, Military Health System, IHS), and a wholly-owned subsidiary, Nitiloop Ltd., contributes the NovaCross microcatheter portfolio acquired in 2022 to support an integrated endovascular ecosystem.

Customer adoption to date includes Emory Healthcare (world's first adopter), Tampa General Hospital (first in Florida), a Pennsylvania academic center, a Michigan health system, a North Carolina multi-hospital network, and multiple Boston-area hospitals across seven-plus U.S. states. The company has raised approximately $148 million cumulatively across multiple 2023–2025 registered direct offerings and preferred investment option exercises, including a $92.2 million potential raise in September 2025, with market capitalization reported at approximately $162 million as of April 2026. Q1 2026 generated approximately $105K–$110K in first commercial revenue, with Q2 2026 already exceeding that total.

Name

Microbot Medical

Legal name

Microbot Medical, Inc.

Website

https://microbotmedical.com

Company type

Public

Founded year

2012

Operating status

Operating

Headcount range

11–50 employees

Short description

Microbot Medical (NASDAQ: MBOT) develops and commercializes the LIBERTY Endovascular Robotic System, a first-of-its-kind single-use, remotely operated robotic platform for peripheral endovascular procedures that reduces physician radiation exposure by 92%. The company sells disposable LIBERTY units to U.S. hospital systems and academic medical centers, recently transitioning from limited to full market release in April 2026.

Ownership category

akta.pro rank

Product category

Endovascular Surgical Robotics

NAICS

Electromedical and Electrotherapeutic Apparatus Manufacturing (334510)

SIC

Surgical & Medical Instruments & Apparatus (3841)

akta.pro primary industry

Surgical Robotics & Computer-Assisted Surgery Platforms (HLAHADAF)

akta.pro secondary industry

Healthcare & Assistive Robotics (HDAAAIAC)

Keywords

• Endovascular robotics
• Surgical robotics
• Medical devices
• Interventional radiology
• Robotic surgery

Headquarters

HQ city

Hingham

HQ country

United States

HQ region

North America

Offices2 records

Markets served

GTM type

B2B

Offering type

Hardware or Manufacturing

Cost components

Technology or R&D, Personnel, Operations, Marketing or Sales, Supply Chain, Infrastructure

Revenue model

1. LIBERTY Endovascular Robotic System (Hardware): The company sells its single-use LIBERTY Endovascular Robotic System. The system is fully disposable, with each procedure requiring a new unit. Currently in early commercialization phase following FDA clearance in September 2025, generating initial commercial revenue in Q1 2026. Q2 2026 revenue already exceeding Q1 totals.
2. Israel Innovation Authority Grant: Non-dilutive grant funding from Israel Innovation Authority (~ $440,000) to support manufacturing process development, linked to future sales royalties.

Pricing tiers

Go-to-market motion3 records

Distribution channels4 records

Marketing channels6 records

Core offering

Microbot Medical develops, manufactures, and commercializes the LIBERTY Endovascular Robotic System, a single-use, remotely operated robotic platform for peripheral vascular procedures. The system enables physicians to navigate guidewires and catheters remotely from a seated position away from radiation, integrating with existing hospital workflows and eliminating the need for capital-intensive surgical robotics infrastructure. The company also offers the NovaCross Microcatheter family acquired from Nitiloop Ltd. to support its endovascular product ecosystem.

Product overview

Microbot Medical offers a unified product portfolio centered on the LIBERTY Endovascular Robotic System, a single-use, remotely operated robotic platform for peripheral endovascular procedures. The system incorporates AccuGrip™ technology for secure wire and catheter manipulation. Following the 2022 acquisition of Nitiloop, the portfolio was expanded to include the NovaCross Microcatheter family. The company is developing the LIBERTY Starter Kit as a bundled offering to lower barriers to adoption. The company has received FDA 510(k) clearance and commenced limited market release in late 2025, followed by full market release in April 2026.

Differentiator

Problem solved

Functional benefit

Brands

• LIBERTY® Endovascular Robotic System: First single-use, remotely operated endovascular robotic system for peripheral vascular procedures with 92% radiation reduction and sub-5-minute setup time.

Products and services

• LIBERTY Endovascular Robotic System The first single-use, remotely operated endovascular robotic system designed for peripheral vascular procedures. Enables physicians to control guidewires and catheters remotely from a seated position, reducing radiation exposure by 92% while providing precise, controlled navigation with sub-5-minute setup. Targets interventional radiologists and vascular surgeons at hospitals and academic medical centers.
• NovaCross Microcatheter Family FDA-cleared microcatheter family acquired from Nitiloop Ltd., designed to enhance the LIBERTY Robotic System portfolio and develop a comprehensive robotic ecosystem for endovascular procedures.

Quantifiable outcome

• 92% relative reduction in radiation exposure for physicians (ACCESS-PVI Study)
• +4 more outcomes

Named customers8 records

Segments3 records

Ideal customer profiles2 records

Technology focussed Yes

API detail

Has API

No

API docs

API detail

Core technology

AI maturity

App detail

Feature5 records

Partnerships

One partnership is on record.

• Lovell Government ServicescoreChannel Partner/ Reseller/ Distributor · 18 June 2026Microbot Medical partnered with Lovell Government Services to expand access to its LIBERTY endovascular robotic system through federal healthcare systems serving U.S. veterans, active-duty service members, and Native American communities. Lovell serves as Microbot's service-disabled veteran-owned small business vendor to access Veterans Health Administration, Military Health System, and Indian Health Service facilities via Federal Supply Schedule contracts. Activation expected in Q3 2026. The LIBERTY System is listed on GSA Advantage, Defense Logistics Agency's ECAT, and Department of War's DAPA procurement platforms, reaching 2,000+ government healthcare facilities.

Scale indicators15 records

Recent moves6 records

Expansion highlights6 records

Direct peers

• Penumbra: U.S.-based medtech company specializing in endovascular procedures including peripheral vascular and neurovascular thrombectomy. Comparable as a peer serving interventional radiologists and vascular specialists with novel devices, though Penumbra focuses on catheter-based aspiration rather than robotic platforms.
• Stereotaxis: Developer of robotic magnetic navigation systems for cardiac and peripheral vascular catheter-based interventions. Comparable as a direct endovascular robotics competitor with a similar capital-purchase model and target clinician base in interventional cardiology and radiology.
• Siemens Healthineers (Corindus): Acquired Corindus Vascular Robotics, which developed the CorPath GRX robotic system for percutaneous coronary and peripheral vascular interventions. Most directly comparable endovascular robotic peer; however, Corindus uses a capital-purchase model, contrasting with LIBERTY's single-use approach.

Broad incumbents

• Medtronic: Global medtech incumbent that has entered surgical robotics with the Hugo platform and has a broad peripheral vascular intervention portfolio. Comparable as a potential large entrant that could leverage its installed hospital relationships to compete with LIBERTY.
• Abbott: Global medtech leader with significant peripheral vascular intervention portfolio. Comparable as a broad incumbent serving interventional cardiologists and vascular surgeons, representing both a customer-base overlap and a competitive threat to LIBERTY's adoption.
• Boston Scientific: Major peripheral vascular intervention device company (angioplasty balloons, stents, drug-coated balloons). Comparable as a peer in the peripheral endovascular market where LIBERTY's robotic system is deployed, though Boston Scientific is a device vendor rather than a robotics player.
• Intuitive Surgical: Dominant surgical robotics incumbent (da Vinci platform) with multibillion-dollar installed base across U.S. hospitals. Comparable as the established leader in computer-assisted surgery that LIBERTY competes against for hospital robotics budgets, though Intuitive is focused on laparoscopic rather than endovascular procedures.
• Stryker: Owner of the Mako surgical robotics platform (orthopedics), expanding into other surgical robotics applications. Comparable as an established surgical robotics incumbent with strong hospital relationships, though currently focused on orthopedic rather than endovascular procedures.
• Johnson & Johnson (Auris Health / Monarch): Auris Health (acquired by J&J) developed the Monarch robotic platform for bronchoscopy and other endoluminal procedures. Comparable as a deep-pocketed surgical robotics incumbent with hospital sales channels that could be redirected toward peripheral vascular applications.

Emerging players

• Robocath: French company developing the R-One robotic platform for coronary and peripheral vascular interventions. Comparable emerging European peer in endovascular robotics with CE Mark approval, directly competing for the same customer segment LIBERTY targets once it secures CE Mark.

Market position

Strengths4 records

Weaknesses4 records

Competitive moat5 records

Key risks6 records

Key highlights7 records

Customer concentration

• LinkedInlinkedin.com/company/microbot-medical
• Xx.com/microbotmedical
• Facebookfacebook.com/microbotmedical

Compliance2 records

Revenue estimate

Valuation estimate

Number of profiles

Profiles18 records

Subsidiaries1 record

Funding overview

Funding rounds14 records

Investors2 records

Funding detail is available on the Subscription and Enterprise plan.Contact sales →

M&A1 record

Investments

M&A and investment is available on the Subscription and Enterprise plan.Contact sales →

Frequently asked questions about Microbot Medical